Effect of the MAO-B inhibitor and glutamate modulator safinamide on depressive symptoms in three Parkinson’s disease patients
Objective: Patients suffering from Parkinson’s disease experience various motor and non-motor symptoms. Within the range of non-motor symptoms depression is reported as high as in…Ceftriaxone improves motor function in a rat hemi-parkinsonian model: Potential to delay bilateral progression of motor deficits in Parkinson’s disease
Objective: This study sought to evaluate the impact of ceftriaxone, as a potential repurposed drug, in ameliorating motor decline in a unilateral rat 6-hydroxydopamine (6-OHDA)…Safinamide improves motor symptoms severity and daily living in Parkinson’s Disease (PD) patients
Objective: To evaluate the clinical effects of safinamide, administered as add-on therapy to levodopa in fluctuating PD patients, on symptoms severity and daily living. Background:…Effects of safinamide and rasagiline on in vivo glutamate release in 6-OHDA hemilesioned rats
Objective: To investigate the effects of safinamide (saf) and rasagiline on in vivo glutamate (Glu) release in the 6-hydroxydopamine (6-OHDA) hemilesioned rat model of Parkinson’s…Safinamide reduces membrane excitability and synaptic transmission of striatal spiny projection neurons in a rat model of Parkinson’s disease
Objective: The effect of safinamide (saf) on the electrical membrane properties and both excitatory and inhibitory synaptic transmission of striatal spiny projection neurons (SPNs) was…Neural plasticity based on the change of the glutamate receptors: Repetition of electrical stimulation for the reduction of Parkinsonian symptoms
Objective: This study investigated the fundamental mechanism how the repeated electrical stimulation (ES) affects the reduction of parkinsonian symptoms. Background: The reduced parkinsonian symptoms by…Change of extracellular glutamate and GABA level in striatum during deep brain stimulation of the entopeduncular nucleus in rats
Objective: Globus pallidus interna (GPi) is recognized as an effective treatment for advanced Parkinson’s disease. However, the neurochemical basis of its effects remains unknown. The…Relationship between symptoms and regional density of metabotropic glutamate receptors subtype 1 measured with 11C-ITMM PET in de novo Parkinson’s disease
Objective: To investigate correlations of motor and non-motor symptoms with the brain densitiesof the metabotropic glutamate receptor subtype 1 (mGluR1) in de novo Parkinson’s disease…Alterations of cortical metabotropic glutamate receptor-mediated signaling in patients with Parkinson’s disease
Objective: To evaluate expression of brain metabotropic glutamatergic receptor 5 and the relationship with clinical measures in Parkinson’s disease patients. Background: Metabotropic glutamate receptor 5…Anti-glutamatergic effect of safinamide in Parkinson’s Disease: A TMS study
Objective: To test the effect of safinamide, at the doses of 50 and 100 mg/day, on primary motor cortex (M1) excitability and glutamatergic neurotransmission in…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.